In the wake of the increase in Current Liabilities in the first quarter 2025, Quick Ratio fell to 0.04 a new company low.

Within Major Pharmaceutical Preparations industry 527 other companies have achieved higher Quick Ratio than Kineta Inc in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 3500 to 4793.

Explain Quick Ratio?
How much Cash & cash equivalents KANT�s has?
What are KANT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

KANT Quick Ratio	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1
Y / Y Current Liabilities Change	-9.82 %	-4.03 %	-12.12 %	-0.77 %	-31.38 %
Y / Y Cash & cash equivalent Change	-82.85 %	-89.04 %	-74.23 %	-88.42 %	-80.81 %
Quick Ratio MRQ	0.04	0.1	0.29	0.1	0.22
KANT's Total Ranking	# 4793	# 3500	# 1205	# 2867	# 2544
Seq. Current Liabilities Change	18.19 %	-6.43 %	-28.02 %	13.28 %	25.78 %
Seq. Cash & cash equivalent Change	-52.05 %	-67.47 %	116.56 %	-49.24 %	-69.34 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 528
Healthcare Sector	# 1031
Overall Market	# 4793

Quick Ratio Statistics
High	Average	Low
15.69	4.64	0.04
(Dec 31 2018)		(Mar 31 2025)

Financial Statements
Kineta Inc 's Current Liabilities	$ 7 Millions	Visit KANT's Balance sheet
Kineta Inc 's Cash & cash equivalent	$ 0 Millions	Visit KANT's Balance sheet
Source of KANT's Sales		Visit KANT's Sales by Geography

Cumulative Kineta Inc 's Quick Ratio

KANT's Quick Ratio for the trailling 12 Months

KANT Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-6.51 %	-14.13 %	-24.02 %	-11.45 %	7.01 %
Y / Y Cash & cash equivalent TTM Growth	-83.45 %	-82.68 %	-72.41 %	-51.4 %	-22.83 %
Quick Ratio TTM	0.13	0.17	0.34	0.51	0.72
Total Ranking TTM	# 3511	# 2419	# 3320	# 2671	# 2848
Seq. Current Liabilities TTM Growth	-2.65 %	-0.86 %	-2.92 %	-0.23 %	-10.58 %
Seq. Cash & cash equivalent TTM Growth	-27.95 %	-49.49 %	-35.04 %	-30.02 %	-24.59 %

Quick ratio ranking by company, industry and sector >> Back to KANT Financial Strength Comparisons >> Go to Compare KANT Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in KANT's Current Liabilities to $7.40 millions, cumulative Quick Ratio to 0.13 below the KANT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 451 other companies have achieved higher Quick Ratio than Kineta Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 2419 to 3511.

Explain Quick Ratio?
How much Cash & cash equivalents KANT�s has?
What are KANT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 452
Healthcare Sector	# 932
Within the Market	# 3511

trailing twelve months Quick Ratio Statistics
High	Average	Low
9.52	3.92	0.08
(Sep 30 2019)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Dr Reddy s Laboratories Limited	0.11	$ 172.000 Millions	$ 1,527.000 Millions
Blue Water Vaccines Inc	0.11	$ 1.577 Millions	$ 14.039 Millions
Takeda Pharmaceutical Company Limited	0.09	$ 2,553.695 Millions	$ 28,661.027 Millions
The Greater Cannabis Company Inc	0.09	$ 0.046 Millions	$ 0.530 Millions
Neurosense Therapeutics Ltd	0.08	$ 0.213 Millions	$ 2.516 Millions
NIKA PHARMACEUTICALS, INC	0.07	$ 0.019 Millions	$ 0.269 Millions
Provectus Biopharmaceuticals Inc	0.07	$ 0.390 Millions	$ 5.735 Millions
Galectin Therapeutics Inc	0.07	$ 7.431 Millions	$ 110.840 Millions
Amneal Pharmaceuticals Inc	0.06	$ 65.770 Millions	$ 1,075.824 Millions
Aditxt Inc	0.05	$ 0.502 Millions	$ 11.012 Millions
Lexaria Bioscience Corp	0.04	$ 0.074 Millions	$ 1.793 Millions
Kineta Inc	0.04	$ 0.304 Millions	$ 7.401 Millions
Hcw Biologics Inc	0.04	$ 1.108 Millions	$ 27.142 Millions
Lakeshore Biopharma Co Ltd	0.04	$ 4.391 Millions	$ 113.654 Millions
Northwest Biotherapeutics Inc	0.03	$ 2.779 Millions	$ 83.059 Millions
Abvc Biopharma Inc	0.03	$ 0.217 Millions	$ 6.731 Millions
Lunai Bioworks Inc	0.03	$ 0.923 Millions	$ 28.842 Millions
Cnbx Pharmaceuticals Inc	0.03	$ 0.046 Millions	$ 1.462 Millions
Emmaus Life Sciences Inc	0.02	$ 1.333 Millions	$ 64.915 Millions
Nexien Biopharma Inc	0.02	$ 0.008 Millions	$ 0.459 Millions
Protagenic Therapeutics Inc new	0.01	$ 0.015 Millions	$ 1.077 Millions
Sunshine Biopharma Inc	0.01	$ 0.070 Millions	$ 5.762 Millions
Propanc Biopharma Inc	0.01	$ 0.051 Millions	$ 4.341 Millions
Scorpius Holdings inc	0.01	$ 0.249 Millions	$ 23.140 Millions
Accustem Sciences Inc	0.01	$ 0.036 Millions	$ 3.707 Millions

Date modified: 2026-09-26T07:27:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.